The retrospective study to evaluate the efficacy and safety of Solubilized Liquid Polycaprolactone injection for Periorbital Rejuvenation in Thailand

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20250909007

Enrollment

Registered

2025-09-09

Start date

2025-09-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wrinkles and skin laxity around the eyes Periorbital rejuvenation, Polycaprolactone, PCL

Interventions

polycaprolactone treatment for skin rejuvenation around the periorbital area

Treatment

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 20 and 60 years, both male and female. 2. Volunteers who received polycaprolactone treatment for skin rejuvenation around the periorbital area. 3. Volunteers who participated in the study titled Efficacy and Safety of Polycaprolactone for Facial Skin Rejuvenation in Thailand (COA Si. 582/2023).

Exclusion criteria

Exclusion criteria: No exclusion criteria for this retrospective study

Design outcomes

Primary

Measure	Time frame
Texture Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Wrinkles Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Pigmentation Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Redness Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Physician improvement scale Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Quartile scale,Safety Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Adverse event	—

Measure

Time frame

Texture Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Wrinkles Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Pigmentation Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Redness Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Physician improvement scale Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Quartile scale,Safety Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Adverse event

—

Secondary

Measure	Time frame
Pores Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Volume depression Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Volume changes Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Vectra	—

Measure

Time frame

Pores Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Volume depression Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Antera 3D,Volume changes Baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9 and 12 months after 3rd treatment Vectra

—

Countries

Thailand

Contacts

Public ContactRungsima Wanitphakdeedecha

Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university

rungsima.wan@mahidol.ac.th024192667

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026